Needle Free Drug Delivery Devices Market Size, Share, Growth, Trends and Forecasts, 2014 To 2022: Grand View Research

The needle-free drug delivery market is expected to upsurge due to the increasing incidence of transmittable diseases such as Hepatitis B and AIDS, and also chronic diseases like diabetes. According to 2013 data by the World Health Organization (WHO), 35 million people worldwide are living with HIV/AIDS, out of which Sub-Saharan Africa covers 71% of the total population suffering from HIV.

The International Diabetes Federation 2014 update has diagnosed 387 million people worldwide with diabetes and predicts that these figures would go up by 205 million till 2035. The WHO has stated that 2,000 million people are affected with hepatitis with descending prevalence in Sub-Saharan Africa, China, and North America. One of the reasons for the transmission of these diseases is through needle; hence to combat this, industry players are coming up with needle-free drug delivery.

Request to Sample of This Report @

The needle-free drug delivery devices market is segmented on the basis of types and procedures. Power injection, liquid injection, and depot and projectile injection are the types of needle-free drug delivery devices. The delivery of needle-free devices may be through reservoir patches or matrix patches coming under transdermal drug delivery. Reservoir-type patches offer better-controlled release as compared to matrix-type, and hence are highly preferred. The depot injection has its application in case of muscle therapy, where a timely, slow, and continuous release is required. Among the drug delivery systems, the oral drug delivery system is widely used due to patient convenience and easy absorption across intestinal epithelium in the bloodstream.

The needle-free drug delivery devices market has its presence in North America, Europe, Asia Pacific, Latin America, and MEA. The Food and Drug Administration records 0.7% death and 0.6% disability due to use of contaminated injections. The U.S. National Library of Medicine in October 2013 assessed a needle-free delivery for vaccination against avian influenza. Bioject Medical Technologies, a developer and manufacturer of needle-free injection therapy system appointed iHealthNet LLC, an advanced and cost-effective health care provider for its exclusive distribution of Biojector2000 in North America.

Major players of the needle-free drug delivery devices market include Bioject, Antares Pharma Inc., Injex, Westonn Medical, and Aradigm. Continuous upgrading of devices and its development, collaborations with regional distributors, and expansion of facilities are expected to drive the needle-free device market over the forecast period. On March 2015, Antares Pharma announced FDA-approval of its needle-free injector, TEV-TROPIN(R) 10 mg. In addition, in May 2012, FDA waved a green signal for the manufacture and export of INJEX 30 in the U.S. market, which is anticipated to propel market growth in future.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

For More Information, Visit Grand View Research


Sherry James

Corporate Sales Specialist, U.S.A.

Grand View Research, Inc.

United States

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519


Blog Site: